MHRA paediatric investigation plan
Live attenuated respiratory syncytial virus (RSV) (Live attenuated respiratory syncytial virus (RSV))
MHRA paediatric investigation plan MHRA-100584-PIP02-23 · Agreement
Key facts
| PIP number | MHRA-100584-PIP02-23 |
|---|---|
| Active substances | Live attenuated respiratory syncytial virus (RSV) |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of respiratory syncytial virus (RSV) disease |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Jan 6, 2025 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: